|
We performed a review of events subsequent to
the balance sheet date through the date the financial statements were issued and determined, except as disclosed herein, that there
were no other such events requiring recognition or disclosure in the financial statements.
| |
● |
From February 2, 2015 through March 30 2015 the Company signed 11 notes
for convertible debt totaling $1,121,250. |
| |
|
|
| |
● |
From January 15, 2015 through March 19, 2015 the Company signed 3 merchant debt agreements for approximately $330,000 in
net proceeds. |
| |
|
|
| |
● |
The Company repaid convertible notes along with prepayment penalties and accrued interest of $646,201. |
| |
|
|
| |
● |
January 21, 2015, we announced we had received over $1.16 million during the previous two months from equity investments and that we planned to expand marketing, sales and operations capabilities. |
| |
|
|
| |
● |
February 10, 2015 we announced we had received to first order for our Barozyme HT48 High Throughput System |
| |
|
|
| |
● |
February 19, 2015 we announced we had been awarded a $1,000,000 NIH SBIR Phase II Grant to support the development of a high-throughput, automated, high pressure based DNA Shearing System |
| |
|
|
| |
● |
March 12, 2015 we announced the release of PCT-HD "The Next Generation Protein Preparation System" |
|